785 reports of this reaction
3.1% of all DIROXIMEL FUMARATE reports
#5 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #5 most commonly reported adverse reaction for DIROXIMEL FUMARATE, manufactured by Biogen Inc.. There are 785 FDA adverse event reports linking DIROXIMEL FUMARATE to PRODUCT DOSE OMISSION ISSUE. This represents approximately 3.1% of all 25,327 adverse event reports for this drug.
Patients taking DIROXIMEL FUMARATE who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is moderately reported among DIROXIMEL FUMARATE users, representing a notable but not dominant share of adverse events.
In addition to product dose omission issue, the following adverse reactions have been reported for DIROXIMEL FUMARATE:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 785 FDA reports for DIROXIMEL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 3.1% of all adverse event reports for DIROXIMEL FUMARATE, making it a notable side effect.
If you experience product dose omission issue while taking DIROXIMEL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.